TECHWIRE 30
(CIX: WRAL30)  1,091.62  down arrow-7.83  (-0.71 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NQ: Apple)  93.74  down arrow-1.09  (-1.15 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NY: Q)  69.07  down arrow-0.91  (-1.3 %)  Updated: 08:04 PM EDT, Apr 29 2016
(OP: BASFY)  79.82  up arrow+1.02  (1.3 %)  Updated: 05:20 PM EDT, Apr 29 2016
(NQ: BCRX)  3.26  down arrow-0.06  (-1.81 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NQ: BDSI)  3.38  down arrow-0.15  (-4.25 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NQ: CEMP)  16.93  down arrow-0.46  (-2.65 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NQ: Cisco)  27.49  down arrow-0.47  (-1.68 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NQ: CREE)  24.51  down arrow-0.75  (-2.97 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NQ: DARA)  0.88    (0 %)  Updated: 08:10 PM EST, Dec 04 2015
(NY: EMC)  26.11  down arrow-0.08  (-0.31 %)  Updated: 08:04 PM EDT, Apr 29 2016
(NQ: EXTR)  3.51  up arrow+0.17  (5.09 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NQ: Facebook)  117.58  up arrow+0.85  (0.73 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NY: GSK)  42.91  down arrow-0.45  (-1.04 %)  Updated: 08:04 PM EDT, Apr 29 2016
(NQ: Alphabet)  693.01  up arrow+1.99  (0.29 %)  Updated: 08:10 PM EDT, Apr 29 2016
(NY: IBM)  145.94  down arrow-1.13  (-0.77 %)  Updated: 08:04 PM EDT, Apr 29 2016

Posts tagged “Chimerix ”

Updated March 1

Premium Lock Chimerix discloses 20% slashing of work force after drug trial failure

Failure of a potential transplant treatment in a late-stage clinical trial triggered more than an 80 percent plunge in the price of Chimerix shares two months ago. The Durham drug development firm on Monday disclosed it had slashed its work force by 20 percent and also was cutting R&D spending.

Chimerix 80% dive in December Chimerix 80% dive in December

February 22

Premium Lock CH joins Smart City effort; Cree rallies on upgrade; Chimerix stock plunges; Uber driver in shooting; Facebook Messenger update

Bulldog In today's Bulldog wrapup of tech and life science news: Chapel Hill joins AT&T Smart City initiative; analyst's upgrade sends Cree shares up; Chimerix shares plunge on bad clinical trial news; Uber says one of its drivers was involved in the Michigan shootings; and Facebook updates Messenger.

February 9

Premium Lock Durham-based Chimerix reports progress in smallpox vaccine

Bioterror     Chimerix, which has a contract potentially worth more than $400 million in the development of a first vaccine targeting smallpox, reports progress in development of an antiviral. In recent tests, its brincidofovir successfully treated 100 percent of animals infected with rabbitpox.

January 1

Premium Lock Chimerix shows new life after big hedge fund investment

After a big drug trial failure and an 80 percent collapse of its stock on Monday, Durham-based drug firm Chimerix was basically written off by numerous analysts. But Chimerix is far from dead, especially after a big investment from Point72, a major Wall Street hedge fund.

Busy, up-and-down day for Chimerix stock Busy, up-and-down day for Chimerix stock

Updated December 30, 2015

Premium Lock Chimerix stock rallies 11% despite analysts' downgrades

Some big Wall Street analysts downgraded Chimerix on Tuesday after Monday's big drug trial failure news that triggered an 81 percent drop in its shares. But investors weren't all scared away as buying drove up Chimerix by more than 11 percent in heavy trading.

Chimerix surges Chimerix surges

Updated December 29, 2015

Premium Lock Wall Street turns on former Durham darling Chimerix after drug failure

Failure of its lead drug in a Stage 3 clinical trial led to a fiscal bloodbath and a tsunami of bad publicity Monday for Durham-based Chimerix. A darling of investors and a company once seen as developing a cure for Ebola, the firm's stock "crater" by more than 81%.

Chimerix 80% dive in December Chimerix 80% dive in December

September 14, 2015

Premium Lock Chimerix gets cash infusion to continue work on smallpox treatment

Forgotten Smallpox Durham-based Chimerix, Inc. (NASDAQ:CMRX) announced a 15-month extension Monday to allow the company to continue work on a treatment for smallpox.

Updated June 18, 2015

Premium Lock 30-minute delivery by drone?; Chimerix raises $175M; new BIO name; chips squeeze biz; Facebook's new app

Bulldog In today's Bulldog wrapup of tech and life science news: Amazon foresees delivery by drones in 30 minutes; Chimerix raises $175 million in stock sale; a new name for BIO organization; new chips squeeze small businesses; and Facebook unveils new photo app.

June 11, 2015

Premium Lock Chimerix raising $150M; Jawbone-Fitbit fight; Spotify tunes up with $115M; Tesla's SUV coming; TransEnterix raising money

In today's Bulldog wrapup of technology and life science news: Durham-based Chimerix looks to raise $150 million for drug development; Jawbone sues Fitbit - again; Spotify raises $115 million to fight Apple; Tesla's SUV is coming soon; and RTP-based TransEnterix looks to raise money for robotic surgery system.

January 23, 2015

Premium Lock First GSK Ebola vaccine doses shipping to Africa for trial

Ebola Drug giant GlaxoSmithKline is shipping the first few hundred doses of its vaccine that is being tested as a treatment for Ebola to Africa for further testing. GSK will soon begin testing the vaccine for efficacy. Currently there is no successful treatment for the deadly disease.

December 15, 2014

Premium Lock RTP drug firm launching clinical trial of possible Ebola treatment

Ebola RTP-based BioCryst Pharmaceuticals is launching a clinical trial of a potential treatment for Ebola with funding support from the U.S. government. Durham-based Chimerix and GSK also are involved in the Ebola battle.

Updated December 11, 2014

Premium Lock Backers pledge $390M for Ebola; side effects delay one trial

Ebola Even as backers pledged $390 million for Ebola vaccines, Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects. It's not the vaccine being tested by GlaxoSmithKline.

Updated December 9, 2014

Premium Lock NC firms help lead Ebola fight but face multiple battles

Several North Carolina firms are at the forefront of developing new treatments for the Ebola virus, but they face challenges in testing and delivering them, executives from Chimerix, Quintiles and GlaxoSmithKline say at a conference in RTP.

GSK's Donna Altenpohl GSK's Donna Altenpohl

Updated December 9, 2014

Premium Lock North Carolina's role in fighting Ebola highlights conference in RTP

Ebola North Carolina's role in fighting the Ebola epidemic striking western Africa and a disease that is a global threat will be discussed Monday at a conference in Research Triangle Park.

Updated December 5, 2014

Premium Lock Ebola NC: Conference to focus on state's role, preparations in fighting outbreak

Ebola Government, health, private sector executives will gather at a conference focusing on the Ebola outbreak and North Carolina's involvement as well as preparations for a possible health crisis here.

Updated December 1, 2014

Premium Lock Lost amid layoff news: GSK's advance toward Ebola vaccine

The Ebola outbreak isn't generating big headlines in the U.S. these days, but forthcoming layoffs at GlaxoSmithKline are a hot topic. Unfortunately for GSK, the job cuts have overshadowed the company's progress in developing the first vaccine for the deadly Ebola.

GSK's Andrew Witty talks strategy GSK's Andrew Witty talks strategy

November 19, 2014

Premium Lock Bill Gates helps fund Durham drug firm's Ebola fight

Billionaire Bill Gates and his foundation are providing financial support to Durham-based Chimerix, helping it ramp up production of a potential vaccine for the deadly Ebola virus.

Bloodmobile leaves RDU for Liberia Bloodmobile leaves RDU for Liberia

November 14, 2014

Premium Lock Chimerix drug chosen for Ebola tests in Africa

Ebola An international consortium says it will test an antiviral drug from Durham-based Chimerix on patients with Ebola in Africa. The Wellcome Trust is providing the funding.

October 30, 2014

Premium Lock Durham-based Chimerix gears up Ebola tests, raising $105M

Ebola Chimerix is gearing up for the FDA- approved to launch a Phase 2 clinical trial of its possible treatment for Ebola. The company also is looking to raise $105 million.

October 21, 2014

Premium Lock GSK's Ebola vaccine could be tested in January, WHO says

Ebola Tens of thousands of doses of experimental Ebola vaccines -including one from GlaxoSmithKline - could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith